- Home
- IMCR vs SPT Comparison
IMCR vs SPT Comparison
Compare IMCR & SPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- SPT
- Stock Information
- Founded
- IMCR 2008
- SPT 2010
- Country
- IMCR United Kingdom
- SPT United States
- Employees
- IMCR N/A
- SPT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- SPT Computer Software: Prepackaged Software
- Sector
- IMCR Health Care
- SPT Technology
- Exchange
- IMCR Nasdaq
- SPT Nasdaq
- Market Cap
- IMCR 1.5B
- SPT 1.1B
- IPO Year
- IMCR 2021
- SPT 2019
- Fundamental
- Price
- IMCR $32.80
- SPT $21.20
- Analyst Decision
- IMCR Buy
- SPT Buy
- Analyst Count
- IMCR 10
- SPT 13
- Target Price
- IMCR $58.13
- SPT $31.69
- AVG Volume (30 Days)
- IMCR 444.9K
- SPT 598.6K
- Earning Date
- IMCR 08-07-2025
- SPT 07-31-2025
- Dividend Yield
- IMCR N/A
- SPT N/A
- EPS Growth
- IMCR N/A
- SPT N/A
- EPS
- IMCR N/A
- SPT N/A
- Revenue
- IMCR $333,581,000.00
- SPT $418,413,000.00
- Revenue This Year
- IMCR $26.82
- SPT $12.32
- Revenue Next Year
- IMCR $8.15
- SPT $11.90
- P/E Ratio
- IMCR N/A
- SPT N/A
- Revenue Growth
- IMCR 25.75
- SPT 17.79
- 52 Week Low
- IMCR $23.15
- SPT $18.52
- 52 Week High
- IMCR $41.54
- SPT $39.75
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- SPT 51.77
- Support Level
- IMCR $30.76
- SPT $19.88
- Resistance Level
- IMCR $33.95
- SPT $21.63
- Average True Range (ATR)
- IMCR 1.39
- SPT 0.63
- MACD
- IMCR -0.15
- SPT 0.11
- Stochastic Oscillator
- IMCR 43.05
- SPT 81.39
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.